HK1146270A1 - Proline analogs as ligands for cannabinoid receptors for the treatment of pain - Google Patents
Proline analogs as ligands for cannabinoid receptors for the treatment of painInfo
- Publication number
- HK1146270A1 HK1146270A1 HK11100388.7A HK11100388A HK1146270A1 HK 1146270 A1 HK1146270 A1 HK 1146270A1 HK 11100388 A HK11100388 A HK 11100388A HK 1146270 A1 HK1146270 A1 HK 1146270A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ligands
- pain
- treatment
- cannabinoid receptors
- proline analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1044708P | 2008-01-08 | 2008-01-08 | |
| PCT/IB2009/000023 WO2009087564A1 (en) | 2008-01-08 | 2009-01-08 | Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1146270A1 true HK1146270A1 (en) | 2011-05-20 |
Family
ID=40474987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11100388.7A HK1146270A1 (en) | 2008-01-08 | 2011-01-14 | Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8084612B2 (xx) |
| EP (2) | EP2583963A1 (xx) |
| JP (1) | JP5236748B2 (xx) |
| KR (1) | KR101343399B1 (xx) |
| CN (1) | CN101910126B (xx) |
| AU (1) | AU2009203549B2 (xx) |
| BR (1) | BRPI0905681A2 (xx) |
| CA (2) | CA2794054C (xx) |
| HK (1) | HK1146270A1 (xx) |
| IL (2) | IL206355A0 (xx) |
| MX (1) | MX2010007622A (xx) |
| NZ (1) | NZ586094A (xx) |
| WO (1) | WO2009087564A1 (xx) |
| ZA (1) | ZA201004059B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2350548B1 (es) * | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciència I Tecnologia, S.A. | N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| EP2565190B1 (en) | 2010-04-28 | 2015-06-03 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
| CA2807000C (en) | 2010-08-24 | 2018-12-04 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| US9062032B2 (en) * | 2011-10-27 | 2015-06-23 | Astellas Pharma Inc. | Aminoalkyl-substituted N-thienylbenzamide derivative |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| ES2008634A6 (es) | 1988-10-06 | 1989-07-16 | Lilly Sa | Un procedimiento para la produccion de derivados de tiofeno. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB9304156D0 (en) * | 1992-03-26 | 1993-04-21 | Zeneca Ltd | Antibiotic compounds |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| DE69635048T2 (de) | 1995-06-12 | 2006-02-16 | G.D. Searle & Co. | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| GB9525262D0 (en) | 1995-12-11 | 1996-02-07 | Bayer Ag | Heterocyclylcarbonyl substituted benzofuranyl-ureas |
| CA2309338A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| JP4667867B2 (ja) * | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換フロ［２，３−ｂ］ピリジン誘導体 |
| US6852748B1 (en) * | 2002-10-30 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide |
| ES2378071T3 (es) * | 2004-03-24 | 2012-04-04 | Janssen Pharmaceutica Nv | Moduladores de cannabinoides de tetrahidro-indazol |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| TW200602314A (en) * | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| JP4760139B2 (ja) * | 2004-05-28 | 2011-08-31 | 田辺三菱製薬株式会社 | ピロリジン誘導体およびその製法 |
| CN1960970A (zh) * | 2004-05-28 | 2007-05-09 | 田边制药株式会社 | 作为cb1受体的拮抗剂的吡咯烷衍生物 |
| FR2880890B1 (fr) | 2005-01-19 | 2007-03-30 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique |
| JP2007262022A (ja) * | 2006-03-29 | 2007-10-11 | Mochida Pharmaceut Co Ltd | 新規２−チオフェンカルボキサミド誘導体 |
-
2009
- 2009-01-08 CA CA2794054A patent/CA2794054C/en active Active
- 2009-01-08 JP JP2010541858A patent/JP5236748B2/ja active Active
- 2009-01-08 CA CA2711508A patent/CA2711508C/en active Active
- 2009-01-08 KR KR1020107017700A patent/KR101343399B1/ko active IP Right Grant
- 2009-01-08 MX MX2010007622A patent/MX2010007622A/es active IP Right Grant
- 2009-01-08 CN CN200980101878.1A patent/CN101910126B/zh not_active Expired - Fee Related
- 2009-01-08 EP EP12198206.0A patent/EP2583963A1/en not_active Withdrawn
- 2009-01-08 US US12/350,450 patent/US8084612B2/en active Active
- 2009-01-08 NZ NZ586094A patent/NZ586094A/en not_active IP Right Cessation
- 2009-01-08 AU AU2009203549A patent/AU2009203549B2/en not_active Ceased
- 2009-01-08 WO PCT/IB2009/000023 patent/WO2009087564A1/en active Application Filing
- 2009-01-08 BR BRPI0905681-5A patent/BRPI0905681A2/pt not_active Application Discontinuation
- 2009-01-08 EP EP09701185.2A patent/EP2240443B1/en active Active
-
2010
- 2010-06-08 ZA ZA2010/04059A patent/ZA201004059B/en unknown
- 2010-06-14 IL IL206355A patent/IL206355A0/en active IP Right Grant
-
2011
- 2011-01-14 HK HK11100388.7A patent/HK1146270A1/xx not_active IP Right Cessation
-
2013
- 2013-06-06 IL IL226799A patent/IL226799A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2711508C (en) | 2013-07-16 |
| EP2583963A1 (en) | 2013-04-24 |
| CA2794054C (en) | 2014-11-25 |
| AU2009203549B2 (en) | 2013-03-07 |
| CA2794054A1 (en) | 2009-07-16 |
| BRPI0905681A2 (pt) | 2015-07-07 |
| WO2009087564A1 (en) | 2009-07-16 |
| IL206355A0 (en) | 2010-12-30 |
| JP2011509285A (ja) | 2011-03-24 |
| EP2240443A1 (en) | 2010-10-20 |
| JP5236748B2 (ja) | 2013-07-17 |
| NZ586094A (en) | 2012-06-29 |
| KR101343399B1 (ko) | 2013-12-19 |
| KR20100113556A (ko) | 2010-10-21 |
| CN101910126A (zh) | 2010-12-08 |
| MX2010007622A (es) | 2011-01-21 |
| US8084612B2 (en) | 2011-12-27 |
| CN101910126B (zh) | 2014-04-30 |
| US20090291947A1 (en) | 2009-11-26 |
| EP2240443B1 (en) | 2013-11-20 |
| IL226799A0 (en) | 2013-07-31 |
| CA2711508A1 (en) | 2009-07-16 |
| AU2009203549A1 (en) | 2009-07-16 |
| ZA201004059B (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1148435A1 (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
| IL205671A0 (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases | |
| ZA200902374B (en) | Compositions useful for the treatment of diabetes | |
| EP2320907A4 (en) | THERAPEUTIC COMPOUNDS | |
| PT2303021T (pt) | Compostos para tratamento do cancro | |
| ZA201101739B (en) | Compounds for the treatment of hepatitis c | |
| EP2365815A4 (en) | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP2268285A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0806794D0 (en) | Therapeutic compounds | |
| IL211313A0 (en) | Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies | |
| GB0813740D0 (en) | Therapeutic compounds | |
| HK1208802A1 (en) | Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease vps10p- | |
| ZA201006827B (en) | Carboxamide-heteroaryl derivatives for the treatment of diabetes | |
| PL2247297T3 (pl) | Działanie terapeutyczne w stanach chorobowych płuc | |
| GB0804755D0 (en) | Therapeutic compounds | |
| IL226799A0 (en) | Proline analogs as ligands for cannabinoid receptors for pain relief | |
| IL211189A0 (en) | Compounds for the treatment of peripheral neuropathies | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| EP2358200A4 (en) | BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES | |
| IL207190A (en) | A process for ultra-purification of alginates | |
| IL207668A0 (en) | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain | |
| IL208624A0 (en) | Compositions for the treatment of lice | |
| PL2323625T3 (pl) | Nowa kompozycja do leczenia pigmentacji wybroczynowych | |
| GB0817857D0 (en) | Compounds for the treatment of neoplasia | |
| GB0819536D0 (en) | Compounds for the treatment of neoplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210102 |